For analysis of blood count response to SGLT‐2 inhibitor treatment in humans with SCD, pre‐ and on‐medication blood counts were analysed in 25 patients meeting criteria described in methods. This evidence concerns the gene SLC5A2 and Schnyder corneal dystrophy.